Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
UbCxGARJQfEQ4x9B
